ST PHARM CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 93,400 KRW | +5.06% |
|
+10.66% | +37.76% |
| 2023 | ST Pharm Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
| 2021 | ST Pharm Co.,Ltd. Announces Expansion of Oligonucleotide Facility | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
STPharm Co.,Ltd. is a Korea-based company principally engaged in manufacture of pharmaceutical products. The Company's products mainly consist of generic active pharmaceutical ingredients (APIs), such as tipepidine hibenzate, doxifluridine, clopidogrel bisulfate, voriconazole and new medicine APIs, such as small molecule APIs. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
93,400
KRW
Average target price
105,556
KRW
Spread / Average Target
+13.01%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +37.76% | 1.28B | |
| +33.25% | 699B | |
| +26.29% | 571B | |
| -3.55% | 364B | |
| +18.16% | 326B | |
| +4.36% | 286B | |
| +15.13% | 236B | |
| +5.05% | 198B | |
| -10.31% | 194B | |
| -3.69% | 149B |
- Stock Market
- Equities
- A237690 Stock
- News ST Pharm Co.,Ltd.
- Market Chatter: ST Pharm to Launch mRNA-based COVID-19 Vaccine in 2022
